Church & Dwight
CHD · What the business does, what can go wrong, and how options sellers approach it
What it does
Church & Dwight is a consumer products company best known for Arm & Hammer baking soda. Over time it has used that brand name on many household and personal care items, including laundry detergent, cat litter, deodorant, and toothpaste.
The company also owns other brands, such as OxiClean, Batiste dry shampoo, TheraBreath oral care, and Hero acne patches. It also has a specialty products business that sells ingredients to industrial and agricultural customers. Most of its sales come from the United States.
How it makes money
It sells everyday products through large retailers, such as grocery chains, mass merchants, drugstores, warehouse clubs, and online marketplaces. Revenue depends on how many units sell and on pricing. Profit depends on the gap between what products sell for and what ingredients, packaging, freight, and marketing cost.
The company has also grown by acquiring smaller brands and then expanding their distribution.
Why investors own it
- Demand for household staples tends to be steady, even when the economy slows.
- A mix of brands in many categories means no single product drives everything.
- Management has a record of buying brands and integrating them.
- The company has paid a dividend for a long time, which appeals to income-focused investors.
What can go wrong
- Retailers' private-label products can pull shoppers away, especially when budgets are tight.
- Commodity, packaging, and shipping costs can squeeze margins if the company cannot raise prices.
- Acquisitions can disappoint or cost more than expected.
- Heavy reliance on a few large retail customers gives those customers negotiating power.
- Newer brands can lose momentum if trends shift.
What to watch
- Organic sales growth, split between volume and price
- Gross margin trends
- Marketing spending as a share of sales
- Results from recently acquired brands
- Retailer inventory changes and shelf-space decisions
- Debt levels after acquisitions
- Dividend announcements
Options income angle
Options on CHD are generally available across several expirations, but they are usually less active than options on the largest consumer staples names. Bid-ask spreads can be wider, especially on strikes far from the current price.
Implied volatility tends to be modest. It usually rises ahead of quarterly earnings and when guidance or input costs are in question.
A caution for premium sellers: staples stocks can drop sharply on a single weak report or outlook cut. A covered call or cash-secured put can leave you exposed to that move, while the premium collected is typically small.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 12, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Church & Dwight grew net sales 1.6% to $6,203.2 million in 2025 while reshaping its portfolio: it bought Touchland, exited three small product lines and sold its vitamin business. Reported earnings per share rose sharply because 2024 carried a large impairment (a write-down of an asset's value). Excluding charges, per-share earnings rose only 2.6%. Walmart concentration, private label competition, tariffs and a weakening Waterpik brand are the main pressure points.
How the business did
- Net sales were $6,203.2 million. Acquisitions added 1.9%, volumes 0.8%, and product line exits subtracted 1.0%. Consumer Domestic was $4,774.8 million (up 0.9%), Consumer International $1,129.4 million (up 5.4%) and the Specialty Products Division $299.0 million (down 1.4%).
- Gross margin fell 100 basis points (hundredths of a percentage point) to 44.7%. Exit costs and a prior-year tariff refund each accounted for 50 basis points. Excluding them, it was flat. Operating margin rose to 17.4% from 13.3%, mainly because 2024 included a $357.1 million non-cash vitamin impairment.
- Diluted earnings per share were $3.02 versus $2.37. Excluding charges, they were $3.53 versus $3.44.
- Cash from operations was $1,215.4 million. The company returned $1,187.2 million to stockholders: $900.0 million of share repurchases and $287.2 million of dividends.
- Unusual items: a pre-tax charge of $45.6 million for exiting Flawless, Spinbrush and Waterpik showerheads, and a one-time pre-tax charge of $58.5 million on the vitamin sale. Touchland cost $656.0 million net of cash acquired, with another $159.0 million due in the first half of 2026.
Risks specific to this company
- Walmart was approximately 23% of net sales, and the top four customers approximately 44%. Business runs on individual orders rather than long-term contracts, and many customers can end agreements on short notice.
- Some of the largest customers launched private label brands in 2025. The filing names stain fighters, diagnostic kits and oral analgesics as categories where retailers push cheaper store brands.
- Waterpik is losing distribution and consumer demand as shoppers pick value brands. Its trade name carried $644.7 million, with fair value at 117% of carrying value, down from 135%. Further declines could trigger an impairment charge.
- Tariffs and higher manufacturing costs weigh on margins. Higher costs of 180 basis points were offset by productivity programs of 160 basis points. The company stopped importing substantially all Waterpik flossers from China into the U.S.
- The company had approximately $2,205.0 million of total consolidated indebtedness. Its revolving credit facility has covenants, and management says it expects to stay within the maximum leverage ratio.
- Seven "power brands" make up approximately 70% of net sales and profits, a substantial share of revenue comes from laundry detergent, and approximately 82% of sales are in the U.S.
What management is watching
- Tariff mitigation: shifting production, finding alternative suppliers and "surgical pricing". Management believes existing tariff cost exposure will be mitigated.
- Long-term targets: growing Arm & Hammer from a $2 billion brand to a $3 billion brand, global oral care from $1 billion to $1.5 billion behind TheraBreath, and international from $1 billion to $2 billion with a focus on M&A.
- Capital spending is expected to be approximately $130.0 million in 2026, including manufacturing capacity for TheraBreath and Sterimar and an ERP (enterprise software) project.
- Capital return: the quarterly dividend rose 4.2%, from $0.295 to $0.3075 per share. $228.9 million of repurchase availability remains under the 2021 program.
- Measures the filing points to include global online sales at 21.4% of consumer sales, a cash conversion cycle of 20 days versus 28, and earnings per share excluding charges.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 30, 2026, filed October 30, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Church & Dwight's third-quarter profit grew much faster than its sales. Net sales rose 1.0% to $1,602.1 million, while income from operations (profit before interest and taxes) rose 14.5% to $291.4 million. Strong volume growth, productivity savings and lower marketing spending outweighed cost inflation, and the company says it received tariff refunds that reduced its costs.
How the business did
- Quarter: Diluted earnings per share were $0.89, up 18.7% from $0.75. Gross margin rose 170 basis points (a basis point is one hundredth of a percentage point) to 46.8%. Marketing expenses fell 6.0% to $190.7 million.
- Sales drivers: Product volumes added 4.6%, but exited businesses (including the divested vitamin business) subtracted 6.1%. Acquisitions added 1.9%. Productivity programs lifted gross margin by 150 basis points. Higher manufacturing and transportation costs took away 180 basis points, partly offset by tariff refunds.
- Segments: Consumer Domestic net sales were $1,225.1 million, up 0.4%. Consumer International was $297.4 million, up 2.5%. The Specialty Products Division was $79.6 million, up 5.0%.
- Nine months: Net sales were $4,601.4 million, up 0.9%, and diluted earnings per share were $2.65, up 10.0% from $2.41.
- Cash and capital return: Operating cash flow for nine months was $841.2 million, versus $852.0 million a year earlier. The company said part of the working capital benefit came from extending payment terms with certain vendors. It paid $219.6 million in dividends and spent $37.1 million on share repurchases, and it completed the $300.0 million cash purchase of the Miss Mouth's brand.
What management is watching
- Costs: The Middle East conflict has disrupted shipping and raised commodity and transportation costs. Management believes it can mitigate a significant portion of these impacts in 2026. It also believes its existing tariff cost exposure will be mitigated through supply chain changes and pricing.
- Tariff refunds: The company paid approximately $23.0 million in IEEPA tariffs (tariffs the Supreme Court ruled unlawful) and received approximately $17.1 million in refunds in the quarter. It intends to put refund proceeds into consumer-facing activities and to offset inflation.
- Spending and capital: Capital expenditures are expected to be approximately $125.0 million in 2026, covering THERABREATH and Sterimar capacity and a new enterprise software project. On October 27, 2026, the board approved a new $1,000.0 million share repurchase program with no expiration date. In October the company bought 1.4 million shares for $130.2 million.
- Measures cited: Management points to its cash conversion cycle (the days needed to turn inventory and receivables into cash, net of payables), which was 17 days versus 26 a year earlier. Its $425.0 million of 3.15% notes mature August 1, 2027, and the company held $446.9 million in cash.
Follow CHD in Kortex
The Kortex app shows CHD's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.